GRI Bio (GRI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Sep, 2026Executive summary
The annual meeting will be held virtually on November 4, 2026, to enhance accessibility and reduce costs and environmental impact.
Stockholders as of September 22, 2026, are eligible to vote on key proposals, including director elections, auditor ratification, and equity plan amendments.
Proxy materials, including the 2025 annual report, are available online, and multiple voting methods are provided.
Voting matters and shareholder proposals
Election of W. Marc Hertz, Ph.D., and David Szekeres as Class III directors until 2029.
Ratification of WithumSmith + Brown, PC as independent auditor for fiscal year 2026.
Approval of an amendment to the 2018 Equity Incentive Plan to increase shares by 546,529 and extend the evergreen provision to January 1, 2036.
Approval of any adjournment of the meeting to solicit additional proxies if needed.
Board of directors and corporate governance
The board consists of five members, three of whom are independent, with an independent chairperson.
Committees include audit, compensation, and nominating/governance, all with independent members.
Directors are evaluated for independence and diversity in background and skills.
Stockholder proposals and director nominations must follow detailed procedures and deadlines.
Latest events from GRI Bio
- Net loss narrowed, cash runway extends to Q2 2027, but funding and Nasdaq listing risks persist.GRI
Q2 2026 - Q1 2026 net loss narrowed to $2.0M; GRI-0621 showed strong safety and cash runway into Q2 2027.GRI
Q1 2026 - Lead candidate improved lung function and fibrosis biomarkers in IPF, with strong safety data.GRI
Corporate presentation - Positive phase 2A IPF results and IND plans for lupus program signal strong pipeline momentum.GRI
Corporate Connect Webinar Series - Strong cash position and positive clinical data support continued pipeline advancement.GRI
Q4 2025 - Biopharma seeks up to $250M for immune therapies, advancing IPF and lupus programs amid high risk.GRI
Registration Filing - Reverse stock split and adjournment proposals approved; results to be filed on Form 8-K.GRI
EGM 2026 - Shareholders to vote on a reverse stock split to help maintain Nasdaq listing and flexibility.GRI
Proxy Filing - Net loss narrowed, cash runway into Q1 2025, but further funding is critical for operations.GRI
Q2 2024